Obox3 Activators
The class of Obox3 activators encompasses a diverse group of chemicals primarily engaging in the enhancement of intracellular cyclic AMP (cAMP) concentrations, which indirectly foster the protein's transcription factor activity. These activators, although not directly interacting with the Obox3 protein, modulate upstream signaling pathways to elicit an environment conducive to its functional activation. Forskolin, by directly stimulating adenylate cyclase, the enzyme responsible for the conversion of ATP to cAMP, initiates a signaling cascade that culminates in the activation of protein kinase A (PKA). PKA, in turn, can phosphorylate transcription factors or coactivators, potentially modulating the transcriptional activity of Obox3. Similarly, Rolipram, IBMX, and Db-cAMP enhance the levels of cAMP through inhibition of phosphodiesterases, preventing the degradation of cAMP, or, in the case of Db-cAMP, by serving as a cAMP analog. Elevated cAMP levels exert their effects through the same PKA-mediated phosphorylation route mentioned for Forskolin. Compounds such as Epinephrine, PGE2, Cholera toxin, PACAP, GLP-1, Histamine, and Dopamine activate G protein-coupled receptors (GPCRs) or other receptor types, leading to adenylate cyclase activation and subsequent cAMP accumulation. This cAMP then broadly engages in the activation of PKA, which indirectly could influence Obox3 activity by priming the transcriptional machinery.
Lastly, Anisomycin represents a unique class within the Obox3 activators as it does not engage the cAMP pathway. Instead, it activates the MAPK pathway, which includes stress-activated protein kinases. The MAPK pathway can modulate a variety of transcription factors and might impinge on Obox3's transcriptional regulation in a less direct manner than cAMP-modulating agents. This chemical class of Obox3 activators, therefore, is united by their common ability to modulate cellular signaling pathways that converge on the regulation of transcription factor activity. Their actions are characterized by the induction of enzymatic activity leading to cAMP production, inhibition of cAMP degradation, or the activation of secondary messenger pathways that ultimately can impact Obox3's role in RNA polymerase II-mediated transcription. While these compounds do not directly bind to or alter Obox3, their effects on cellular signaling pathways provide the means through which Obox3 activity could be indirectly modulated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4). By inhibiting PDE4, Rolipram prevents the breakdown of cAMP within cells. This leads to increased cAMP levels, potentially enhancing the transcriptional activity of genes under the control of Obox3 by similar mechanisms mentioned for Forskolin. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases. By preventing the degradation of cAMP, IBMX could indirectly enhance the transcriptional activity of Obox3-regulated genes through increased cAMP levels and subsequent activation of PKA. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, leading to the activation of adenylate cyclase and an increase in intracellular cAMP levels. This cascade can indirectly affect the transcriptional regulatory effects of Obox3 by modifying the activity of transcription factors or coactivators involved in regulating gene expression. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Dibutyryl cAMP (Db-cAMP) is a cell-permeable cAMP analog. It activates cAMP-dependent pathways by mimicking the action of endogenous cAMP. This can induce changes in the transcriptional regulation by proteins like Obox3 through the activation of PKA, which can phosphorylate proteins involved in RNA polymerase II-mediated transcription. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) can stimulate adenylate cyclase through its interaction with EP receptors, leading to increased cAMP levels. This elevation could promote the activity of transcriptional regulators such as Obox3 by cAMP-dependent signaling pathways and PKA activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates adenylate cyclase, boosting cAMP production. This increase in cAMP can facilitate the potential activation of Obox3-mediated transcription via downstream cAMP-dependent responses such as PKA signaling. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can stimulate adenylate cyclase activity through H2 receptors, leading to increased cAMP levels. This rise in cAMP may potentially amplify the transcriptional regulation by Obox3 through cAMP-dependent mechanisms, including PKA activation. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can elevate cAMP levels via its D1-like receptors, potentially affecting transcriptional regulation by Obox3. This occurs through the engagement of cAMP signaling pathways and the consequential activation of PKA, which may influence transcriptional machinery. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin acts as a potent activator of the MAPK pathway by inducing stress-activated protein kinases (SAPKs). While the connection to Obox3 is less direct, activation of MAPK pathways can modulate transcription factor activity and could potentially influence the transcriptional regulatory effects of Obox3. | ||||||